Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2008-06-18
2010-11-09
Landsman, Robert (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S326000, C530S327000, C514S013800, C514S014800, C424S185100, C424S198100
Reexamination Certificate
active
07829663
ABSTRACT:
The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R), which is a member of the immunoglobulin super family localized on the surface of human platelets, and determined to effect platelet aggregation, secretion, platelet spreading and cellular adhesion. Cloned F11R cDNA and full length F11R cDNA and amino acid sequences are provided. F11R-antagonists and methods for the prevention and treatment of thrombosis, atherosclerosis, heart attacks, stroke and other clinical disorders involving thrombus formation are also provided.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5051448 (1991-09-01), Shashoua
patent: 5169862 (1992-12-01), Burke, Jr. et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5559103 (1996-09-01), Gaeta et al.
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5665701 (1997-09-01), Kornecki et al.
patent: 6150502 (2000-11-01), Strachan
patent: 6358707 (2002-03-01), Gupta et al.
patent: 6699688 (2004-03-01), Kornecki et al.
patent: 2004/0115135 (2004-06-01), Quay
patent: 0 045 665 (1982-02-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 184 187 (1986-06-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 99/02561 (1999-01-01), None
patent: WO 2004/063327 (2004-07-01), None
Karsan A. et al., “The Blood Vessel Wall”,In Hematology: Basic Principles and Practice, 3rdEd.1770-1782 (2000).
Cines D.B. et al., “Endothelial Cells in Physiology and in the Pathophysiology of Vascular Disorders”,Blood91(10):3527-3561 (1998).
May A.E. et al., “The Relevance of Blood Cell-Vessel Wall Adhesive Interactions for Vascular Thrombotic Disease”,Thrombosis and Haemostasis82(2):962-970 (1999).
Diquélou A. et al., “Relationship Between Endothelial Tissue Factor and Thrombogenesis Under Blood Flow Conditions”,Thrombosis and Haemostasis74(2):778-783 (1995).
Dardik R. et al., “Recombinant Fragment of Von Willebrand Factor AR545C Inhibits Platelet Binding to Thrombin and Platelet Adhesion to Thrombin-Treated Endothelial Cells”,British Journal of Haematology109:512-518 (2000).
André P. et al., “Platelets Adhere to and Translocate on Von Willebrand Factor Presented by Endothelium in Stimulated Veins”,Blood96(10):3322-3328 (2000).
Rosenblum W.I. et al., “Role of Platelet-Endothelial Cell Adhesion Molecule (PECAM) in Platelet Adhesion/Aggregation Over Injured but Not Denuded Endothelium In Vivo and Ex Vivo”,Stroke27(4):709-711 (1996).
Bombeli T. et al., “Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIa-Dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3Integrin, and GPIbα”,J. Exp. Med.187(3):329-339 (1998).
Verheul H.M.W. et al., “Vascular Endothelial Growth Factor-Stimulated Endothelial Cells Promote Adhesion and Activation of Platelets”,Blood96(13):4216-4221 (2000).
Kornecki E. et al., “Activation of Human Platelets by a Stimulatory Monoclonal Antibody”,The Journal of Biological Chemistry265(17):10042-10048 (1990).
Naik U.P. et al., “Mechanisms of Platelet Activation by a Stimulatory Antibody: Cross-Linking of a Novel Platelet Receptor for Monoclonal Antibody F11 with the FcγRII Receptor”,Biochem. J.310:155-162 (1995).
Martin-Padura I. et al., “Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration”,The Journal of Cell Biology142(1):117-127 (1998).
Kornecki E. et al., “Identification of a Unique Type of Thrombopathy of Human Platelets: Defect in the Exposure of Active Fibrinogen Receptors in a Patient with Friedreich's Ataxia”,J. Lab Clin. Med.111:618-626 (1988).
Wang F. et al., “Stimulatory Antibody-Induced Activation and Selective Translocation of Protein Kinase C Isoenzymes in Human Platelets”,Biochem. J.311:401-406 (1995).
Sobocka M. et al., “Molecular Mechanisms of Platelet Activation by a Stimulatory Monoclonal Antibody, Cloning and Potential Pathophysiological Roles for a Novel Platelet Receptor”,Blood90(10),Supplement1 (part 2 of 2):2996 (1997).
Sobocka M.B. et al., “Cloning of the Human Platelet F11 Receptor: A Cell Adhesion Molecule Member of the Immunoglobulin Superfamily Involved in Platelet Aggregation”,Blood95(8):2600-2609 (2000).
Babinska A. et al., “Two Regions of the Human Platelet F11-Receptor (F11R) Are Critical for Platelet Aggregation, Potentiation and Adhesion”,Thromb Haemost87:712-721 (2002).
Ozaki H. et al., “Cutting Edge: Combined Treatment of TNF-α and IFN-γ Causes Redistribution of Junctional Adhesion Molecule in Human Endothelial Cells”,The Journal of Immunology163:553-557 (1999).
Williams L.A. et al., “Identification and Characterisation of Human Junctional Adhesion Molecule (JAM)”,Molecular Immunology36:1175-1188 (1999).
Liu Y. et al., “Human Junction Adhesion Molecule Regulates Tight Junction Resealing in Epithelia”,Journal of Cell Science113:2363-2374 (2000).
Gupta S.K. et al., “Platelet Agonist F11 Receptor Is a Member of the Immunoglobulin Superfamily and Identical with Junctional Adhesion Molecule (JAM): Regulation of Expression in Human Endothelial Cells and Macrophages”,IUBMB Life50:51-56 (2000).
Naik U.P. et al., “Characterization and Chromosomal Localization of JAM-1, a Platelet Receptor for a Stimulatory Monoclonal Antibody”,Journal of Cell Science114(3):539-547 (2000).
Sobocka M.B. et al., “F11 Receptor-Mediated Potentiation of Platelet Activation by Subthreshold Concentrations of Physiological Agonists”,XVIII Congress,Abstract #P1902 (2001).
Babine R.E. et al., “Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design”,Chem. Rev.97:1359-1472 (1997).
Hanessian S. et al., “Design and Synthesis of Conformationally Constrained Amino Acids as Versatile Scaffolds and Peptide Mimetics”,Tetrahedron53(37-39):12789-12854 (1997).
Fletcher M.D. et al., “Partially Modified Retro-Inverso Peptides: Development, Synthesis, and Conformational Behavior”,Chemical Reviews98(2):763-795 (1998).
Morley J.S., “Modulation of the Action of Regulatory Peptides by Structural Modification”,Trends Pharm. Sci.,463-468 (1980).
Hudson D. et al., “Methionine Enkephalin and Isosteric Analogues”,Int. J. Peptide Protein Res.14:177-185 (1979).
Spatola A.F. et al., “Structure-Activity Relationships of Enkephalins Containing Serially Replaced Thiomethylene Amide Bond Surrogates”,Life Sciences38(14):1243-1249 (1986).
Hann M.M. et al., “On the Double Bond Isostere of the Peptide Bond: Preparation of an Enkephalin Analogue”,J. Chem. Soc. Perkin Trans. I,307-314 (1982).
Almquist R.G. et al., “Synthesis and Biological Activity of a Ketomethylene Analogue of a Tripeptide Inhibitor of Angiotensin Converting Enzyme”,Journal of Medicinal Chemistry23(12):1392-1398 (1980).
Jennings-White C. et al., “Synthesis of Ketomethylene Analogs of Dipeptides”,Tetrahedron Letters23(25):2533-2534 (1982).
Holladay M.W. et al., “Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres”,Tetrahedron Letters24(41):4401-4404 (1983).
Hruby V.J., “Conformational Restrictions of Biologically Active Peptides Via Amino Acid Side Chain Groups”,Life Sciences31(3):189-199 (1982).
Eldred C.D. et al., “Orally Active Non-Peptide Fibrinogen Receptor (GpIIb/IIIa) Antagonists: Identification of 4-[4-[4-(Aminoimino-methyl)phenyl]-1-piperazinyl]-1-piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic Agen
Babinska Anna
Ehrlich Yigal H.
Kornecki Elizabeth
Hissong Bruce D
Landsman Robert
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
F11 receptor (F11R) antagonists as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with F11 receptor (F11R) antagonists as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and F11 receptor (F11R) antagonists as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179695